Literature DB >> 21717292

Drugs of abuse, dopamine, and HIV-associated neurocognitive disorders/HIV-associated dementia.

Vishnudutt Purohit1, Rao Rapaka, David Shurtleff.   

Abstract

Although the incidence of HIV-associated dementia (HAD) has declined, HIV-associated neurocognitive disorders (HAND) remain a significant health problem despite use of highly active antiretroviral therapy. In addition, the incidence and/or severity of HAND/HAD are increased with concomitant use of drugs of abuse, such as cocaine, marijuana, and methamphetamine. Furthermore, exposure to most drugs of abuse increases brain levels of dopamine, which has been implicated in the pathogenesis of HIV. This review evaluates the potential role of dopamine in the potentiation of HAND/HAD by drugs of abuse. In the brain, multiplication of HIV in infected macrophages/microglia could result in the release of HIV proteins such as gp120 and Tat, which can bind to and impair dopamine transporter (DAT) functions, leading to elevated levels of dopamine in the dopaminergic synapses in the early asymptomatic stage of HIV infection. Exposure of HIV-infected patients to drugs of abuse, especially cocaine and methamphetamine, can further increase synaptic levels of dopamine via binding to and subsequently impairing the function of DAT. This accumulated synaptic dopamine can diffuse out and activate adjacent microglia through binding to dopamine receptors. The activation of microglia may result in increased HIV replication as well as increased production of inflammatory mediators such as tumor necrosis factor (TNF)-alpha and chemokines. Increased HIV replication can lead to increased brain viral load and increased shedding of HIV proteins, gp120 and Tat. These proteins, as well as TNF-alpha, can induce cell death of adjacent dopaminergic neurons via apoptosis. Autoxidation and metabolism of accumulated synaptic dopamine can lead to generation of reactive oxygen species (hydrogen peroxide), quinones, and semiquinones, which can also induce apoptosis of neurons. Increased cell death of dopaminergic neurons can eventually lead to dopamine deficit that may exacerbate the severity and/or accelerate the progression of HAND/HAD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21717292     DOI: 10.1007/s12035-011-8195-z

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  77 in total

1.  Enhancement of central nervous system pathology in early simian immunodeficiency virus infection by dopaminergic drugs.

Authors:  S Czub; E Koutsilieri; S Sopper; M Czub; C Stahl-Hennig; J G Müller; V Pedersen; W Gsell; J L Heeney; M Gerlach; G Gosztonyi; P Riederer; V ter Meulen
Journal:  Acta Neuropathol       Date:  2001-02       Impact factor: 17.088

2.  HIV-1 proviral DNA load across neuroanatomic regions of individuals with evidence for HIV-1-associated dementia.

Authors:  R K Fujimura; K Goodkin; C K Petito; R Douyon; D J Feaster; M Concha; P Shapshak
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1997-11-01

3.  Methamphetamine rapidly decreases vesicular dopamine uptake.

Authors:  J M Brown; G R Hanson; A E Fleckenstein
Journal:  J Neurochem       Date:  2000-05       Impact factor: 5.372

Review 4.  Cocaine, metamfetamine, and MDMA abuse: the role and clinical importance of neuroadaptation.

Authors:  Donna Seger
Journal:  Clin Toxicol (Phila)       Date:  2010-08       Impact factor: 4.467

5.  HIV-1 viral proteins gp120 and Tat induce oxidative stress in brain endothelial cells.

Authors:  Tulin Otamis Price; Nuran Ercal; Ryota Nakaoke; William A Banks
Journal:  Brain Res       Date:  2005-04-19       Impact factor: 3.252

6.  Nigral degeneration in acquired immune deficiency syndrome (AIDS).

Authors:  M G Reyes; F Faraldi; C S Senseng; C Flowers; R Fariello
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

Review 7.  Anti-HIV drug distribution to the central nervous system.

Authors:  S A Thomas
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

8.  HIV-1 Tat protein-induced rapid and reversible decrease in [3H]dopamine uptake: dissociation of [3H]dopamine uptake and [3H]2beta-carbomethoxy-3-beta-(4-fluorophenyl)tropane (WIN 35,428) binding in rat striatal synaptosomes.

Authors:  Jun Zhu; Charles F Mactutus; David R Wallace; Rosemarie M Booze
Journal:  J Pharmacol Exp Ther       Date:  2009-03-26       Impact factor: 4.030

9.  The human immunodeficiency virus-1-associated protein, Tat1-86, impairs dopamine transporters and interacts with cocaine to reduce nerve terminal function: a no-net-flux microdialysis study.

Authors:  M J Ferris; D Frederick-Duus; J Fadel; C F Mactutus; R M Booze
Journal:  Neuroscience       Date:  2009-01-20       Impact factor: 3.590

10.  Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs.

Authors:  Dawn D Han; Howard H Gu
Journal:  BMC Pharmacol       Date:  2006-03-03
View more
  74 in total

1.  Nanoparticle based galectin-1 gene silencing, implications in methamphetamine regulation of HIV-1 infection in monocyte derived macrophages.

Authors:  Jessica L Reynolds; Wing Cheung Law; Supriya D Mahajan; Ravikumar Aalinkeel; Bindukumar Nair; Donald E Sykes; Ken-Tye Yong; Rui Hui; Paras N Prasad; Stanley A Schwartz
Journal:  J Neuroimmune Pharmacol       Date:  2012-06-12       Impact factor: 4.147

Review 2.  Cocaine and HIV-1 interplay in CNS: cellular and molecular mechanisms.

Authors:  Shilpa Buch; Honghong Yao; Minglei Guo; Tomohisa Mori; Blaise Mathias-Costa; Vijeta Singh; Pankaj Seth; John Wang; Tsung-Ping Su
Journal:  Curr HIV Res       Date:  2012-07       Impact factor: 1.581

3.  Adolescent HIV-1 transgenic rats: evidence for dopaminergic alterations in behavior and neurochemistry revealed by methamphetamine challenge.

Authors:  Landhing M Moran; Michael Y Aksenov; Rosemarie M Booze; Katy M Webb; Charles F Mactutus
Journal:  Curr HIV Res       Date:  2012-07       Impact factor: 1.581

Review 4.  Comorbid HIV infection and alcohol use disorders: Converging glutamatergic and dopaminergic mechanisms underlying neurocognitive dysfunction.

Authors:  Laura L Giacometti; Jacqueline M Barker
Journal:  Brain Res       Date:  2019-08-14       Impact factor: 3.252

5.  [3H]Dopamine Uptake through the Dopamine and Norepinephrine Transporters is Decreased in the Prefrontal Cortex of Transgenic Mice Expressing HIV-1 Transactivator of Transcription Protein.

Authors:  Matthew Strauss; Bernadette O'Donovan; Yizhi Ma; Ziyu Xiao; Steven Lin; Michael T Bardo; Pavel I Ortinski; Jay P McLaughlin; Jun Zhu
Journal:  J Pharmacol Exp Ther       Date:  2020-05-27       Impact factor: 4.030

Review 6.  Epigenetics, drugs of abuse, and the retroviral promoter.

Authors:  Jasmine Shirazi; Sonia Shah; Divya Sagar; Michael R Nonnemacher; Brian Wigdahl; Zafar K Khan; Pooja Jain
Journal:  J Neuroimmune Pharmacol       Date:  2013-11-12       Impact factor: 4.147

7.  Expression of HIV gp120 protein increases sensitivity to the rewarding properties of methamphetamine in mice.

Authors:  James P Kesby; David T Hubbard; Athina Markou; Svetlana Semenova
Journal:  Addict Biol       Date:  2012-12-18       Impact factor: 4.280

Review 8.  Drug induced increases in CNS dopamine alter monocyte, macrophage and T cell functions: implications for HAND.

Authors:  Peter J Gaskill; Tina M Calderon; Jacqueline S Coley; Joan W Berman
Journal:  J Neuroimmune Pharmacol       Date:  2013-03-01       Impact factor: 4.147

Review 9.  Interplay between Wnt/β-catenin signaling and HIV: virologic and biologic consequences in the CNS.

Authors:  Lena Al-Harthi
Journal:  J Neuroimmune Pharmacol       Date:  2012-10-13       Impact factor: 4.147

10.  Neurobehavioral alterations in HIV-1 transgenic rats: evidence for dopaminergic dysfunction.

Authors:  L M Moran; R M Booze; K M Webb; C F Mactutus
Journal:  Exp Neurol       Date:  2012-10-11       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.